Is the Era of Cancer Vaccines Upon Us?

What Is a Personalized Cancer Vaccine?
What Did the INTerpath-001 Trial Find?
How Does an Individualized mRNA Cancer Vaccine Work?
Does This Mean the Cancer Vaccine Era Has Arrived?
References and Further Reading

Positive Phase 3 results show that a personalized mRNA cancer vaccine combined with pembrolizumab significantly reduces melanoma recurrence and distant metastasis following surgery. Although these findings mark a major advance in cancer immunotherapy, questions surrounding long-term survival benefits, regulatory approval, and manufacturing challenges remain key considerations for the wider clinical adoption of personalized cancer vaccines.

Image credit: sergey kolesnikov/Shutterstock.com

For decades, researchers have explored whether vaccines could train the immune system to recognize and attack cancer cells. While early therapeutic cancer vaccines successfully stimulated immune responses, translating these responses into meaningful clinical benefits has remained challenging.¹

In August 2026, Merck/MSD and Moderna announced positive results from the Phase 3 INTerpath-001 trial, which evaluated intismeran autogene, an investigational personalized mRNA cancer vaccine, alongside pembrolizumab in patients with high-risk melanoma following surgery. The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. According to the companies, this was the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.²

The findings mark an important milestone, but do they signal that personalized cancer vaccines are moving closer to clinical reality, and what challenges remain?

What Is a Personalized Cancer Vaccine?

Conventional vaccines prepare the immune system to recognize infectious agents before they cause disease. Some, such as the human papillomavirus (HPV) vaccine, can also prevent certain cancers by protecting against cancer-causing infections. Therapeutic cancer vaccines, in contrast, are designed for people who already have cancer. Rather than preventing infection, they aim to stimulate immune responses against cancer cells. Personalized cancer vaccines go further by targeting antigens specific to an individual's tumor.¹

These targets, known as neoantigens, can arise when mutations in cancer-cell DNA produce altered proteins. These proteins can be broken down into fragments that differ from those found in healthy cells. Some of these fragments may be recognized as abnormal by T cells, making them potential targets for personalized cancer vaccines.¹

Developing personalized cancer vaccines begins with analyzing tumor and healthy tissue samples. Genomic sequencing identifies mutations specific to the tumor, while bioinformatics tools help predict which mutation-derived fragments could serve as immune targets. For T cells to recognize these fragments, they must first be displayed on cell surfaces by specialized molecules called human leukocyte antigens (HLAs). Because HLA types vary between individuals, researchers use computational tools to predict which neoantigens are most likely to be presented by each patient's HLA molecules. Researchers then select the most promising candidates for inclusion in the vaccine.¹

Video credit: NatureVideoChannel/Youtube.com

What Did the INTerpath-001 Trial Find?

Launched in July 2023, the Phase 3 INTerpath-001 trial investigated whether adding intismeran to pembrolizumab could reduce melanoma recurrence or spread following surgery. The study enrolled 1,137 patients with completely resected stage IIB–IV cutaneous melanoma, randomly assigning them in a 2:1 ratio to receive intismeran plus pembrolizumab or placebo plus pembrolizumab.^2,3

The trial's primary endpoint was recurrence-free survival (RFS), measuring how long patients remained alive without their cancer returning. A key secondary endpoint was distant metastasis-free survival (DMFS), measuring the time before cancer spread to distant parts of the body or death occurred. Both outcomes are particularly important in melanoma, where recurrence after surgery may involve metastatic disease.

In August 2026, Merck and Moderna announced that the trial had met both endpoints, with detailed results following in October. The combination reduced the hazard of recurrence or death by 42% (HR = 0.58) and distant metastasis or death by 38% (HR = 0.62). At two years, recurrence-free survival rates were 82.2% versus 70.0%, while distant metastasis-free survival rates were 88.5% versus 80.2%, representing absolute differences of 12.2 and 8.3 percentage points, respectively. However, longer follow-up is needed to determine whether these benefits translate into improved overall survival.^2,4

The companies released the detailed findings and scheduled them for presentation at the European Society for Medical Oncology (ESMO) 2026 Congress. Although the manuscript had been accepted for publication in The New England Journal of Medicine, the full peer-reviewed paper was not yet available when the October results were announced. For now, intismeran remains investigational, with regulatory approval still required before routine clinical use.⁴

How Does an Individualized mRNA Cancer Vaccine Work?

In the Phase 1 KEYNOTE-603 study, intismeran generated new neoantigen-specific T-cell responses and strengthened existing responses, providing early evidence that the approach can stimulate the intended immune activity.⁶

Intismeran illustrates how selected neoantigens can be incorporated into an individualized mRNA vaccine. Using information obtained through tumor sequencing and computational analysis, researchers design synthetic mRNA encoding up to 34 neoantigens specific to the patient's tumor.⁵

The mRNA is packaged in lipid nanoparticles, which protect it from degradation and help deliver it into cells. Once inside, cells use the mRNA instructions to produce proteins containing the selected neoantigens. These proteins are then processed into smaller fragments and displayed on the surface of antigen-presenting cells through HLA molecules, allowing T cells to recognize them. The goal is to generate new tumor-specific T-cell responses or strengthen existing ones, enabling immune cells to recognize cancer cells carrying the same neoantigens.^5,6

However, recognizing cancer cells does not always translate into an effective immune response. Tumors can suppress T-cell activity through inhibitory pathways such as programmed cell death protein 1 (PD-1). This provides the rationale for combining intismeran with pembrolizumab, an immune checkpoint inhibitor that blocks PD-1 signaling. While the vaccine aims to generate or expand tumor-reactive T cells, pembrolizumab helps relieve inhibitory signaling that can limit their activity, potentially strengthening the overall antitumor response.^1,6

Does This Mean the Cancer Vaccine Era Has Arrived?

The INTerpath-001 findings demonstrate how immunology, genomic sequencing, computational biology, and mRNA manufacturing can be combined to support individualized cancer treatment design. However, the Phase 3 benefit was demonstrated with intismeran combined with pembrolizumab following melanoma surgery, rather than with the vaccine alone, and so it cannot yet be generalized to other cancers or treatment settings.^2,4

Research into personalized cancer vaccination is expanding beyond melanoma. Merck and Moderna's INTerpath program includes trials in non-small cell lung cancer, bladder cancer, and renal cell carcinoma, among other settings, although effectiveness in these cancers remains under investigation.²

Despite these advances, important clinical uncertainties must be addressed before personalized cancer vaccines can become part of routine care. Longer follow-up is needed to determine whether the reported benefits persist and translate into improved overall survival. And although the companies reported no new safety signals, grade 3–5 treatment-related adverse events occurred in 14.2% of patients receiving the combination versus 13.4% receiving pembrolizumab alone. Continued safety monitoring and regulatory approval are also necessary.⁴

Beyond clinical efficacy, practical challenges remain. Researchers must determine which patients are most likely to benefit and improve the accuracy of neoantigen selection. Manufacturing a vaccine tailored to each patient's tumor also requires rapid sequencing, computational analysis, and individualized production, raising questions about treatment timelines, cost, and scalability.¹

Continued advances in neoantigen prediction and individualized vaccine manufacturing may help improve treatment accessibility and support the wider clinical development of personalized cancer vaccines.

References and Further Reading

1. Markosyan N, Vonderheide RH. Developing neoantigen cancer vaccines: where are we now? Nat Commun. 2026 Sep 10;17(1):9700. DOI:10.1038/s41467-026-77532-x, https://www.nature.com/articles/s41467-026-77532-x
2. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma [Internet]. Available from: https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
3. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) [Internet]. Available from: https://clinicaltrials.gov/study/NCT05933577
4. Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium [Internet]. Available from: https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/
5. Ojalvo LS, Posadas T, Chattopadhyay N, Porichis F, Shah S, Cristescu R, et al. Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer. JCO Oncol Adv. 2026 Jul;3(3):e2500206. DOI:10.1200/OA-25-00206, https://ascopubs.org/doi/10.1200/OA-25-00206
6. Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, et al. T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discov. 2024 Nov 1;14(11):2209–23. DOI:10.1158/2159-8290.CD-24-0158, https://aacrjournals.org/cancerdiscovery/article/14/11/2209/749013

Last Updated: Nov 3, 2026